EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
| ChEBI ID | CHEBI:176399 |
| ChEBI Name | inclisiran |
| Stars | |
| Definition | Inclisiran is a long-acting, synthetic small interfering RNA (siRNA) directed against PCSK9. It is indicated for the treatment of primary hypercholesterolemia (familial and non-familial) or mixed dyslipidemia in adults. |
| Last Modified | 14 June 2021 |
| Submitter | Bijay |
| Wikipedia |
|---|
| Roles Classification |
|---|
| Applications: | cardiovascular drug A drug that affects the rate or intensity of cardiac contraction, blood vessel diameter or blood volume. anticholesteremic drug A substance used to lower plasma cholesterol levels. antiatherosclerotic agent A cardiovascular drug that prevents atherosclerosis (a disease in which the inside of an artery narrows due to the build up of plaque). Compare with antiatherogenic agent. renoprotective agent Any compound that is able to prevent damage to the kidneys. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| inclisiran (CHEBI:176399) has role antiatherosclerotic agent (CHEBI:145947) |
| inclisiran (CHEBI:176399) has role anticholesteremic drug (CHEBI:35821) |
| inclisiran (CHEBI:176399) has role cardiovascular drug (CHEBI:35554) |
| inclisiran (CHEBI:176399) has role renoprotective agent (CHEBI:231911) |
| inclisiran (CHEBI:176399) is a organic molecular entity (CHEBI:50860) |
| INNs | Source |
|---|---|
| inclisiran | WHO MedNet |
| inclisiran | WHO MedNet |
| inclisirán | WHO MedNet |
| inclisiranum | WHO MedNet |
| Synonyms | Source |
|---|---|
| ALN-60212 | ChemIDplus |
| ALN-PCSsc | ChemIDplus |
| ALN-PSCsc | ChEMBL |
| Brand Name | Source |
|---|---|
| Leqvio | KEGG DRUG |
| Manual Xrefs | Databases |
|---|---|
| D11931 | KEGG DRUG |
| DB14901 | DrugBank |
| Inclisiran | Wikipedia |
| Registry Numbers | Sources |
|---|---|
| CAS:1639324-58-5 | ChemIDplus |
| Citations |
|---|